RxDoctor Payments Data

Kelly Bistline, APRN

Family · Bonneau, SCNPI 1144947391

Payments from drug & device makers

$2,598in general payments, 2019–2025

Across 106 payments — averaging $24.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$352
  • Novo Nordisk$238
  • Pfizer$231
  • Amgen$221
  • Inari Medical, Inc.$194
  • Corcept Therapeutics$160
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,598100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,598 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$49,039
Medicare patients
189
Services billed
1,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol79$56,856
OzempicSemaglutide45$43,254
EliquisApixaban27$26,342
JardianceEmpagliflozin26$22,949
TrulicityDulaglutide18$20,696
MounjaroTirzepatide14$16,612
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$16,119
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,044
Janumet XrSitagliptin Phos/Metformin Hcl13$10,775
JanuviaSitagliptin Phosphate11$9,582
MyrbetriqMirabegron11$8,032
Esomeprazole Magnesium20$2,480
Atorvastatin Calcium217$2,085
Gabapentin70$2,046
Omeprazole118$1,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$352$72,97699 claims
Novo NordiskOzempic$238$43,25445 claims
Lilly USA, LLCTrulicity, Mounjaro$109$37,30832 claims
PfizerEliquis$231$26,34227 claims
Boehringer IngelheimJardiance$22$22,94926 claims
GSKTrelegy Ellipta$133$16,04420 claims
Astellas Pharma US IncMyrbetriq$30$8,03211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Bonneau

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →